IP Library › Patent Application 11203800
Patent Application
App. No. 11/203,800

Intraductal treatment targeting methylated promoters in breast cancer

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/203,800
Abstract

The invention provides compositions for targeting methylated promoters in breast cancer and pre-cancer patients. The invention also provides methods for intraductal treatment of breast cancer and pre-cancer patients by delivering intraductally an agent that targets methylated promosters of silenced genes.

Claims (11)

1 - 11 . (canceled)

12 . A method for inhibiting DNA methylation of breast cancer genes in a patient having premalignant or malignant breast duct epithelial cells in a breast duct, the method comprising: delivering a composition into the breast duct of the patient, said composition comprising an inhibitor of DNA methylation and a biocompatible solution suitable as a vehicle for delivering the inhibitor of DNA methylation into the breast duct of the patient; thereby inhibiting DNA methylation of breast cancer-related genes within said premalignant or malignant breast duct epithelial cells.

13 . (canceled)

14 . The method of claim 12 wherein the breast cancer genes are selected from the group consisting of cyclin D2, RARbeta2, twist, BRCA1, maspin, estrogen receptor, progesterone receptor, e-cadherin, p16 (INK4a), P15 (INK4b), P14 (ARF), death associated protein (DAP), retinoblastoma Rb, and vonHippel-Lindaur (VHL) gene.

15 . (canceled)

16 . (canceled)

17 . The method of claim 1 12 wherein the DNA methylation inhibitor competitively binds methyl groups and prevents methylation at cytosines.

18 . The method of claim 1 12 wherein the DNA methylation inhibitor is an oligonucleotide directed against a CpG island region of a promoter of a breast cancer related gene.

19 . (canceled)

20 . (canceled)

21 . The method of claim 12 wherein the biocompatible solution is selected from the group consisting of saline, viscous material, and gel material.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2010
From: BREXYS, INC. (FORMERLY WINDY HILL MEDICAL, INC.)
To: LOVE, SUSAN
Reel/Frame 025301/0881 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2008
From: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
To: CYTYC CORPORATION, A SUBSIDIARY OF HOLOGIC, INC.
Reel/Frame 021834/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2008
From: CYTYC CORPORATION
To: WINDY HILL MEDICAL, INC.
Reel/Frame 021840/0558 →
PATENT SECURITY AGREEMENT Recorded Jul 29, 2008
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0879 →
PATENT SECURITY AGREEMENT Recorded Oct 26, 2007
From: CYTYC CORPORATION
To: GOLDMAN SACHS CREDIT PARTNERS L.P.
Reel/Frame 020018/0529 →